Literature DB >> 9676388

Urinary alpha 1-microglobulin detects uropathy. A prospective study in 483 urological patients.

K Everaert1, J Delanghe, C Vande Wiele, P Hoebeke, R A Dierckx, B Clarysse, N Lameire, W Oosterlinck.   

Abstract

PURPOSE: The aim of the study was to evaluate prospectively urinary alpha 1-microglobulin as a marker of proximal tubular damage following acute pyelonephritis and outflow disease of the upper urinary tract in a urological population with minimal exclusion criteria. We also measured the urinary gamma-glutamyltransferase activity, urinary albumin, urinary and serum creatinine, serum IgA and serum alpha 1-microglobulin. PATIENTS AND METHODS: We studied 483 urological patients (age: 1 to 92 years, 297 men, 186 women) excluding patients receiving nephrotoxic drugs, or suffering from type 1 diabetes or renal diseases. There were 141 patients with urinary tract infection but no fever, 36 patients with high fever of non-renal origin, 51 patients with acute pyelonephritis and 156 patients with outflow disease of the upper tract, and 99 patients were included in the reference population.
RESULTS: For acute pyelonephritis, vesico-ureteral reflux, and ureteral obstruction, urinary alpha 1-microglobulin had a sensitivity of 94%, 90% and 63% respectively and a specificity of 67%, 77% and 76%. The area under the curve of the receiver operator characteristic curve was significantly (p < 0.001) higher for urinary alpha 1-microglobulin than for albumin or gamma-glutamyltransferase activity. Unexpected positive results were found in acute prostatitis. The urinary alpha 1-microglobulin was the only parameter which differentiated between acute prostatitis and pyelonephritis (p < 0.001). Creatinine clearance or age had little and gender had no influence on the urinary excretion of alpha 1-microglobulin. Urine production rate significantly increases the urinary alpha 1-microglobulin/creatinine ratio.
CONCLUSION: Our results suggest that the urinary alpha 1-microglobulin/creatinine ratio is a diagnostically useful marker of tubular damage in acute pyelonephritis and vesico-ureteral reflux in the urological population. Following renal colic and chronic ureteral obstruction, a significant increase in urinary alpha 1-microglobulin excretion was observed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9676388     DOI: 10.1515/CCLM.1998.052

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

Review 1.  [Prognostic markers for congenital hydronephroses].

Authors:  S Conrad
Journal:  Urologe A       Date:  2007-02       Impact factor: 0.639

2.  Urinary tract infections in patients with spinal cord injuries.

Authors:  Frederiek D'Hondt; Karel Everaert
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

3.  The level of urinary α1 microglobulin excretion is a useful marker of peritubular capillaritis in antineutrophil cytoplasmic antibody associated vasculitis.

Authors:  Naro Ohashi; Sayaka Ishigaki; Kazuto Kitajima; Naoko Tsuji; Shinsuke Isobe; Takamasa Iwakura; Masafumi Ono; Tomoyuki Fujikura; Takayuki Tsuji; Yukitoshi Sakao; Akihiko Kato; Hideo Yasuda
Journal:  Clin Exp Nephrol       Date:  2014-12-21       Impact factor: 2.801

4.  Evaluation of inflammatory and renal-injury markers in women treated with antibiotics for acute pyelonephritis caused by Escherichia coli.

Authors:  Juan P Horcajada; María Velasco; Xavier Filella; Luisa Alvarez; Elisa De Làzzari; Jose Luis Marín; Blanca Collvinent; Alex Smithson; Jose Antonio Martínez; Mariana Noguero; Jordi Vila; Josep Mensa
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

5.  Procalcitonin, pyuria and proadrenomedullin in the management of urinary tract infections--'triple p in uti': study protocol for a randomized controlled trial.

Authors:  Daniel Drozdov; Anja Thomer; Marc Meili; Stefanie Schwarz; Rita Bossart Kouegbe; Katharina Regez; Merih Guglielmetti; Ursula Schild; Antoinette Conca; Petra Schäfer; Barbara Reutlinger; Cornelia Ottiger; Florian Buchkremer; Alexander Litke; Philipp Schuetz; Andreas Huber; Ulrich Bürgi; Christoph A Fux; Andreas Bock; Beat Müller; Werner C Albrich
Journal:  Trials       Date:  2013-03-22       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.